Company intelligence / Profile preview

Zucara Therapeutics Inc.

Toronto, Ontario, Canadazucara.ca ↗

Ownership: Private
Development stage: Other

Overview

ZT‑01 has completed Phase 1 and Phase 1b trials demonstrating safety and proof-of-concept efficacy. In the Phase 1b study in T1D patients, nearly 90% had a meaningful increase in glucagon after administration with no serious adverse events. The company has initiated a multi-center Phase 2a trial to assess overnight prevention of hypoglycemia in T1D patients using continuous glucose monitoring. Additional nonclinical development for a once-weekly version of ZT‑01 is ongoing.

Therapeutic areas: Endocrinology
Modalities: Small molecule (SSTR2 antagonist)
Industry: Biotech

Drug pipeline

1 asset

ZT-01

Partnerships

Sanofi (strategic investor)JDRF/T1D Fund (“Industry Discovery & Development Partnerships” funding support)Perceptive Xontogeny Venture Fund (“PXV Fund I” investor)

Beyond the preview

Go deeper on Zucara Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zucara Therapeutics Inc..